Skip to main content
Sonoma Pharmaceuticals, Inc. logo

Sonoma Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · SNOA ISIN · US83558L2043 US Manufacturing
Open in API
Filings indexed 951 across all filing types
Latest filing 2026-04-30 Capital/Financing Update
Country US United States of America
Listing US SNOA

About Sonoma Pharmaceuticals, Inc.

https://sonomapharma.com/

Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and commercializes products based on its patented Microcyn® Technology, a stabilized hypochlorous acid (HOCl) platform. With over 20 years of experience, the company produces a range of prescription and over-the-counter solutions for advanced wound care, dermatology, animal health, and eye care. Its products are designed to manage various conditions by promoting healing and reducing the risk of infection. The portfolio serves healthcare professionals in settings like hospitals and nursing homes, as well as consumers for at-home use.

Recent filings

Filing Released Lang Actions
8-K - Sonoma Pharmaceuticals, Inc. (0001367083) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC by Sonoma Pharmaceuticals, Inc. The text describes the entry into a material definitive agreement related to an underwriting agreement for a public offering of common stock and warrants. It details the terms of the offering, the underwriting fees, and related agreements. The document is a current report disclosing a significant event (capital raising through an equity offering) rather than a full financial report or earnings release. The presence of detailed terms about the offering and underwriting agreement indicates this is a Capital/Financing Update. It is not an Annual Report, Earnings Release, or other report types. The document length and content confirm it is not a mere announcement or certification but a substantive filing about financing activity.
2026-04-30 English
424B4 - Sonoma Pharmaceuticals, Inc. (0001367083) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus filed pursuant to Rule 424(b)(4) for a public offering of securities by Sonoma Pharmaceuticals, Inc. It includes detailed information about the offering of units consisting of common stock and warrants, underwriting details, risk factors, use of proceeds, and other legal and financial disclosures typical of a securities offering prospectus. The document is not an annual or quarterly report, earnings release, or management discussion. It is a capital raising document related to financing activities. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is the actual prospectus, not just an announcement or a brief summary.
2026-04-27 English
S-1 - Sonoma Pharmaceuticals, Inc. (0001367083) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used for registering securities for public offering under the Securities Act of 1933. It includes detailed information about the securities being offered, underwriting, risk factors, use of proceeds, and other disclosures typical of a registration statement for an initial or follow-on public offering. This type of filing is related to capital raising activities and financing updates. Therefore, it fits the category of Capital/Financing Update (CAP). The document is not an annual report, earnings release, or any other report type but a registration statement for securities offering.
2026-04-17 English
8-K - Sonoma Pharmaceuticals, Inc. (0001367083) (Filer)
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It reports the entry into a Material Definitive Agreement (a Manufacturing and Supply Agreement) between Sonoma Pharmaceuticals, Inc. and Kenvue Brands LLC. The document does not contain financial statements or detailed financial analysis but rather announces a significant contractual event. The presence of Item 1.01 (Entry into a Material Definitive Agreement) confirms this is a current report about a material event. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories like Annual Report, Earnings Release, or Capital Update.
2026-04-09 English
10-Q Filing
Interim / Quarterly Report Q3 2026
2026-02-10 English
3 Filing
Director's Dealing
2026-02-09 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.